TOP1抗体—艾普蒂

+ +

•  

   

     Western blot analysis using TOP1 mouse mAb against HUVEC (1), Jukat (2),MCF-7 (3),PC-12 (4),Hela (5),NIH/3T3 (6) and HCT116 (7) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using TOP1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using TOP1 mouse mAb (green) and negative control (red).    

  
  

TOP1 antibody, also known as anti-topoisomerase I antibody, is an autoantibody primarily associated with autoimmune diseases, particularly systemic sclerosis (scleroderma). It targets topoisomerase I, a nuclear enzyme essential for DNA replication and repair by relaxing supercoiled DNA through transient single-strand breaks. Discovered in the 1980s, this antibody serves as a key serological marker for diffuse cutaneous systemic sclerosis (dcSSc), a severe subtype characterized by rapid skin thickening and internal organ involvement.

Approximately 20-30% of systemic sclerosis patients test positive for TOP1 antibodies, making it one of the most specific biomarkers for this disease. Its presence correlates with increased risk of pulmonary fibrosis and poorer prognosis. Detection typically employs ELISA or immunoprecipitation techniques using recombinant topoisomerase I antigens. Unlike other antinuclear antibodies, TOP1 antibodies show limited association with non-scleroderma conditions, though rare overlaps with malignancies or liver diseases have been reported.

Research suggests these antibodies may participate in disease pathogenesis through molecular mimicry or sustained immune activation, though their exact pathological role remains debated. Clinically, TOP1 antibody testing aids differential diagnosis between scleroderma subtypes and guides monitoring of visceral complications. Recent studies explore its potential as a therapeutic target, particularly in combination with emerging antifibrotic agents.